MedTrace Logo

Prospective, Multicenter Study on the Association Between Serum Ustekinumab Levels and Clinical, Biological and Endoscopic Remission in Patients With Crohn's Disease.

NCT07100093 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2025-08-03

No results posted yet for this study

Summary

A prospective, non-commercial, multicenter study will be conducted in a cohort of patients initiating induction therapy and a cohort of patients with stable treatment with ustekinumab.

Conditions

  • Ustekinumab Serum Levels in Patients With Crohn´s Disease

Interventions

PROCEDURE

Drug serum levels

Ustekinumab trough levels (prior to administration of the next dose of the drug) will be determined by enzyme-linked immunoadsorption assay (ELISA) methodology.

Sponsors & Collaborators

  • Hospital Universitario La Paz

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-01
Primary Completion
2021-12-30
Completion
2022-02-25

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07100093 on ClinicalTrials.gov